The determination of in vivo envelope-specific cell-mediated immune responses in equine infectious anemia virus-infected ponies

Veterinary Immunology and Immunopathology

Volumn 148, Issue 3-4, 2012, Pages 302-310

  Liu, Chong ^a   Cook, Frank R ^a   Cook, Sheila J ^a   Craigo, Jodi K ^b   Even, Deborah L ^a   Issel, Charles J ^a   Montelaro, Ronald C ^b   Horohov, David W ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Cellular immune responses; DTH; EIAV; Envelope; In vivo; Lentivirus

Indexed keywords

CD20 ANTIGEN; CD3 ANTIGEN; FORMALDEHYDE; GAMMA INTERFERON; INTERLEUKIN 2 RECEPTOR ALPHA; MESSENGER RNA; PARAFFIN; RNA; SODIUM CHLORIDE; VIRUS GLYCOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; EQUINE INFECTIOUS ANEMIA; EQUINE INFECTIOUS ANEMIA VIRUS; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LYMPHOCYTIC INFILTRATION; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PUNCH BIOPSY; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; SKIN BIOPSY; VIRUS ENVELOPE;

ANIMALS; CARRIER STATE; EOSINE YELLOWISH-(YS); EQUINE INFECTIOUS ANEMIA; GENE EXPRESSION REGULATION, VIRAL; HEMATOXYLIN; HORSES; IMMUNITY, CELLULAR; INFECTIOUS ANEMIA VIRUS, EQUINE; REAL-TIME POLYMERASE CHAIN REACTION; VIRAL ENVELOPE PROTEINS;

EQUIDAE; EQUINE INFECTIOUS ANEMIA VIRUS; LENTIVIRUS;

EID: 84865019111     PISSN: 01652427     EISSN: 18732534     Source Type: Journal    
DOI: 10.1016/j.vetimm.2012.06.018     Document Type: Article

References (43)

1. Addo M.M., Yu X.G., Rathod A., Cohen D., Eldridge R.L., Strick D., Johnston M.N., Corcoran C., Wurcel A.G., Fitzpatrick C.A., Feeney M.E., Rodriguez W.R., Basgoz N., Draenert R., Stone D.R., Brander C., Goulder P.J., Rosenberg E.S., Altfeld M., Walker B.D. Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J. Virol. 2003, 77:2081-2092.
2. Ashbridge K.R., Backstrom B.T., Liu H.X., Vikerfors T., Englebretsen D.R., Harding D.R., Watson J.D. Mapping of T helper cell epitopes by using peptides spanning the 19-kDa protein of Mycobacterium tuberculosis. Evidence for unique and shared epitopes in the stimulation of antibody and delayed-type hypersensitivity responses. J. Immunol. 1992, 148:2248-2255.
3. Black C.A. Delayed type hypersensitivity: current theories with an historic perspective. Dermatol. Online J. 1999, 5:7.
4. Black G.F., Fine P.E.M., Warndorff D.K., Floyd S., Weir R.E., Blackwell J.M., Bliss L., Sichali L., Mwaungulu L., Chaguluka S., Jarman E., Ngwira B., Dockrell H.M. Relationship between IFN-gamma and skin test responsiveness to Mycobacterium tuberculosis PPD in healthy, non-BCG-vaccinated young adults in Northern Malawi. Int. J. Tuberc. Lung Dis. 2001, 5:664-672.
5. Breathnach C.C., Sturgill-Wright T., Stiltner J.L., Adams A.A., Lunn D.P., Horohov D.W. Foals are interferon gamma-deficient at birth. Vet. Immunol. Immunopathol. 2006, 112:199-209.
6. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 1987, 162:156-159.
7. Chung C., Mealey R.H., McGuire T.C. CTL from EIAV carrier horses with diverse MHC class I alleles recognize epitope clusters in Gag matrix and capsid proteins. Virology 2004, 327:144-154.
8. Craigo J.K., Leroux C., Howe L., Steckbeck J.D., Cook S.J., Issel C.J., Montelaro R.C. Transient immune suppression of inapparent carriers infected with a principal neutralizing domain-deficient equine infectious anaemia virus induces neutralizing antibodies and lowers steady-state virus replication. J. Gen. Virol. 2002, 83:1353-1359.
9. Craigo J.K., Montelaro R.C. EIAV envelope diversity: shaping viral persistence and encumbering vaccine efficacy. Curr. HIV Res. 2010, 8:81-86.
10. Craigo J.K., Zhang B., Barnes S., Tagmyer T.L., Cook S.J., Issel C.J., Montelaro R.C. Envelope variation as a primary determinant of lentiviral vaccine efficacy. Proc. Natl. Acad. Sci. 2007, 104:15105-15110.
11. Dietert R.R., Bunn T.L., Lee J.E. The delayed type hypersensitivity assay using protein and xenogeneic cell antigens. Methods Mol. Biol. 2010, 598:185-194.
12. Estrada I.C., Gutierrez M.C., Esparza J., Quesada-Pascual F., Estrada-Parra S., Possani L.D. Use of synthetic peptides corresponding to sequences of Mycobacterium leprae proteins to study delayed-type hypersensitivity response in sensitized guinea pigs. Int. J. Lepr. Other Mycobact. Dis. 1992, 60:18-27.
13. Hall J.A., Van Saun R.J., Tornquist S.J., Gradin J.L., Pearson E.G., Wander R.C. Effect of type of dietary polyunsaturated fatty acid supplement (corn oil or fish oil) on immune responses in healthy horses. J. Vet. Intern. Med. 2004, 18:880-886.
14. Hammond S.A., Cook S.J., Lichtenstein D.L., Issel C.J., Montelaro R.C. Maturation of the cellular and humoral immune responses to persistent infection in horses by equine infectious anemia virus is a complex and lengthy process. J. Virol. 1997, 71:3840-3852.
15. Herbein G., Mahlknecht U., Batliwalla F., Gregersen P., Pappas T., Butler J., O'Brien W.A., Verdin E. Apoptosis of CD8+ T cells is mediated by macrophages through interaction of HIV gp120 with chemokine receptor CXCR4. Nature 1998, 395:189-194.
16. Kapsenberg M.L., Wierenga E.A., Bos J.D., Jansen H.M. Functional subsets of allergen-reactive human CD4+ T cells. Immunol. Today 1991, 12:392-395.
17. Kran A.M., Sommerfelt M.A., Baksaas I., Sorensen B., Kvale D. Delayed-type hypersensitivity responses to HIV Gag p24 relate to clinical outcome after peptide-based therapeutic immunization for chronic HIV infection. APMIS 2012, 120:204-209.
18. Kvale D., Kran A.M., Sommerfelt M.A., Nyhus J., Baksaas I., Bruun J.N., Sorensen B. Divergent in vitro and in vivo correlates of HIV-specific T-cell responses during onset of HIV viraemia. AIDS 2005, 19:563-567.
19. Leroux C., Cadore J.L., Montelaro R.C. Equine infectious anemia virus (EIAV): what has HIV's country cousin got to tell us?. Vet. Res. 2004, 35:485-512.
20. Leroux C., Issel C.J., Montelaro R.C. Novel and dynamic evolution of equine infectious anemia virus genomic quasispecies associated with sequential disease cycles in an experimentally infected pony. J. Virol. 1997, 71:9627-9639.
21. Liu C., Betancourt A., Cohen D.A., Adams A.A., Sun L., Horohov D.W. Granzyme B-mRNA expression by equine lymphokine activated killer (LAK) cells is associated with the induction of apoptosis in target cells. Vet. Immunol. Immunopathol. 2011, 143:108-115.
22. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2-[Delta][Delta]CT method. Methods 2001, 25:402-408.
23. Mackall J.C., Bai G.H., Rouse D.A., Armoa G.R., Chuidian F., Nair J., Morris S.L. A comparison of the T cell delayed-type hypersensitivity epitopes of the 19-kD antigens from Mycobacterium tuberculosis and Myco. intracellulare using overlapping synthetic peptides. Clin. Exp. Immunol. 1993, 93:172-177.
24. McGuire T.C., Fraser D.G., Mealey R.H. Cytotoxic T lymphocytes in protection against equine infectious anemia virus. Anim. Health Res. Rev. 2004, 5:271-276.
25. Mealey R.H., Lee J.H., Leib S.R., Littke M.H., McGuire T.C. A single amino acid difference within the alpha-2 domain of two naturally occurring equine MHC class I molecules alters the recognition of Gag and Rev epitopes by equine infectious anemia virus-specific CTL. J. Immunol. 2006, 177:7377-7390.
26. Mealey R.H., Sharif A., Ellis S.A., Littke M.H., Leib S.R., McGuire T.C. Early detection of dominant Env-specific and subdominant Gag-specific CD8+ lymphocytes in equine infectious anemia virus-infected horses using major histocompatibility complex class I/peptide tetrameric complexes. Virology 2005, 339:110-126.
27. Mealey R.H., Zhang B., Leib S.R., Littke M.H., McGuire T.C. Epitope specificity is critical for high and moderate avidity cytotoxic T lymphocytes associated with control of viral load and clinical disease in horses with equine infectious anemia virus. Virology 2003, 313:537-552.
28. Montelaro R.C., Ball J.M., Rushlow K.E. The Retroviridae 1993, Plenum Press, New York.
29. Nishino Y., Kameoka M., Okada Y., Zhong Q., Kimura T., Azuma I., Ikuta K. In vivo induction of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes and delayed-type hypersensitivity by a 23-amino acid peptide from the highly conserved region in major core protein p24. Vaccine 1994, 12:485-491.
30. Poulter L.W., Seymour G.J., Duke O., Janossy G., Panayi G. Immunohistological analysis of delayed-type hypersensitivity in man. Cell. Immunol. 1982, 74:358-369.
31. Ramakers C., Ruijter J.M., Deprez R.H., Moorman A.F. Assumption-free analysis of quantitative real-time polymerase chain reaction (PCR) data. Neurosci. Lett. 2003, 339:62-66.
32. Rwambo P.M., Issel C.J., Hussain K.A., Montelaro R.C. In vitro isolation of a neutralization escape mutant of equine infectious anemia virus (EIAV). Arch. Virol. 1990, 111:275-280.
33. Shearer G.M. HIV-induced immunopathogenesis. Immunity 1998, 9:587-593.
34. Sitz K.V., Loomis-Price L.D., Ratto-Kim S., Kenner J.R., Sau P., Eckels K.H., Redfield R.R., Birx D.L. Delayed-type hypersensitivity skin testing using third variable loop peptides identifies T lymphocyte epitopes in human immunodeficiency virus-infected persons. J. Infect. Dis. 1997, 176:1085-1089.
35. Sitz K.V., Price L.D.L., Kim S.R., Kenner J.R., Sau P., Eckels K.H., Redfield R.R., Birx D.L. Delayed-type hypersensitivity skin testing using third variable loop peptides identifies T lymphocyte epitopes in human immunodeficiency virus-infected persons. J. Infect. Dis. 1997, 176:1085-1089.
36. Sitz K.V., Ratto-Kim S., Hodgkins A.S., Robb M.L., Birx D.L. Proliferative responses to human immunodeficiency virus type 1 (HIV-1) gp120 peptides in HIV-1-infected individuals immunized with HIV-1 rgp120 or rgp160 compared with nonimmunized and uninfected controls. J. Infect. Dis. 1999, 179:817-824.
37. Tagmyer T.L., Craigo J.K., Cook S.J., Even D.L., Issel C.J., Montelaro R.C. Envelope determinants of equine infectious anemia virus vaccine protection and the effects of sequence variation on immune recognition. J. Virol. 2008, 82:4052-4063.
38. Tagmyer T.L., Craigo J.K., Cook S.J., Issel C.J., Montelaro R.C. Envelope-specific T-helper and cytotoxic T-lymphocyte responses associated with protective immunity to equine infectious anemia virus. J. Gen. Virol. 2007, 88:1324-1336.
39. Tumas D.B., Hines M.T., Perryman L.E., Davis W.C., McGuire T.C. Corticosteroid immunosuppression and monoclonal antibody-mediated CD5+ T lymphocyte depletion in normal and equine infectious anaemia virus-carrier horses. J. Gen. Virol. 1994, 75(Pt 5):959-968.
40. Vestweber D. Adhesion and signaling molecules controlling the transmigration of leukocytes through endothelium. Immunol. Rev. 2007, 218:178-196.
41. Waksman B.H. Cellular hypersensitivity and immunity: conceptual changes in last decade. Cell. Immunol. 1979, 42:155-169.
42. Weynants V., Godfroid J., Limbourg B., Saegerman C., Letesson J.J. Specific bovine brucellosis diagnosis based on in vitro antigen-specific gamma interferon production. J. Clin. Microbiol. 1995, 33:706-712.
43. Whelan A.O., Clifford D., Upadhyay B., Breadon E.L., McNair J., Hewinson G.R., Vordermeier M.H. Development of a skin test for bovine tuberculosis for differentiating infected from vaccinated animals. J. Clin. Microbiol. 2010, 48:3176-3181.